Q-omics provides the consensus-scored SSX5 profile across patient tissues and cancer cell-line models. SSX5 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SSX5 is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, SSX5 RNA expression shows 8,936 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, THCA, and THYM as cancer lineages where SSX5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SSX5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SSX5 survival associations across molecular data types. SSX5 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SSX5 RNA expression–survival associations across cancer types. High SSX5 expression shows unfavorable associations in UVM, KICH, ACC, KIRC, LUAD and LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SSX5 RNA expression.
This table summarizes SSX5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for SSX5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SSX5 shows lower tumor expression in BRCA and LUSC and higher tumor expression in THCA, LIHC and KIRP. The THCA box plot shows higher SSX5 RNA expression in tumor versus normal tissue (log2 FC = +0.274, t-test p = .005).
This table shows molecular features associated with SSX5 in patient tissues and cancer cell lines. In patient samples, SSX5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SSX5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
